Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.Financial_Report.xls
10-Q - ERGO 10-Q 09/30/12 - Entia Biosciences, Inc.ergo10q_093012apg.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R36.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R42.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R43.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R40.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R34.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R31.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R29.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R37.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R35.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R32.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R33.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R39.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R28.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R23.htm
EX-32.1 - EXHIBIT 32.1 - Entia Biosciences, Inc.ex32_1apg.htm
EX-31.1 - EXHIBIT 31.1 - Entia Biosciences, Inc.ex31_1apg.htm
EX-32.2 - EXHIBIT 32.2 - Entia Biosciences, Inc.ex32_2apg.htm
EX-31.2 - EXHIBIT 31.2 - Entia Biosciences, Inc.ex31_2apg.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R41.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R38.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R30.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R27.htm
v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (974,602) $ (1,094,903)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on disposal of product line 0 (78,842)
Bad debt expense 0 2,059
Depreciation/amortization 16,290 11,009
Gain on extinguishment of note payable (75,315) 0
Impairment of intangible asset 0 106,642
Amortization of discount on convertible notes 179,110 222,933
Stock-based compensation 420,801 467,131
Changes in operating assets and liabilities:    
Accounts receivable 9,693 (11,433)
Inventory 14,915 (23,501)
Prepaid expenses 21,924 24,930
Other current assets 0 3,792
Accounts payable and accrued expenses 217,395 95,045
Accrued compensation - officer 0 89,398
NET CASH USED IN OPERATING ACTIVITIES (169,789) (185,740)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (14,906) (3,708)
Acquisition of patents and patents pending (57,315) (34,789)
Collections on lease receivable 0 8,304
NET CASH USED IN INVESTING ACTIVITIES (72,221) (30,193)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock, preferred stock and warrants 211,999 143,200
Proceeds from convertible notes payable 13,000 0
Proceeds from notes payable 0 26,438
Proceeds from convertible note payable-related party 25,000 0
Repayment of note payable (9,930) (10,795)
NET CASH PROVIDED BY FINANCING ACTIVITIES 240,069 158,843
NET CHANGE IN CASH (1,941) (57,090)
Cash at beginning of period 16,639 65,061
Cash at end of period 14,698 7,971
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:    
Interest paid 893 1,674
Taxes paid 0 0
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:    
Deemed distribution 21,400 0
Conversion of notes payable to preferred stock 10,000 107,500
Warrants issued for extinguishment of debt 48,533 100,000
Stock issued for license 25,501 0
Stock issued for note receivable 59,000 0
Warrants issued in connection with notes payable $ 27,704 $ 0